C4 Therapeutics
Degrader company whose IKZF1/3 molecular glue cemsidomide showed a 53% response rate in heavily pretreated myeloma and entered phase 2 in 2026.
Cemsidomide (MonoDAC IKZF1/3 degrader) with dexamethasone: 53% ORR at 100 µg in relapsed/refractory myeloma (EHA 2026); phase 2 MOMENTUM first patient February 2026; phase 1b with elranatamab ongoing; further combinations planned 2027.
Pages like this
not linked directly; found by shared links- CompanyMonte Rosa Therapeutics
Shares Molecular glues that break the MYC-MAX partnership, Screen glue-like compounds against every cancer cell line and publish it, Design protein degraders small enough to get into the brain, Molecular glue discovery platforms.
- CompanyKymera Therapeutics
Shares Molecular glues that break the MYC-MAX partnership, Screen glue-like compounds against every cancer cell line and publish it, Design protein degraders small enough to get into the brain, Molecular glue discovery platforms.
- CompanyNurix Therapeutics
Shares Screen glue-like compounds against every cancer cell line and publish it, Design protein degraders small enough to get into the brain, Molecular glue discovery platforms, PROTACs & molecular glues (targeted protein degradation).
- Key paperThe first PROTAC: a chimeric molecule that tags a protein for destruction
Shares Molecular glue discovery platforms, PROTACs & molecular glues (targeted protein degradation), The undruggable drivers.
- TermImmunomodulatory drugs (IMiDs) and CELMoDs
Shares Molecular glue discovery platforms, PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.
- IdeaDegrade the damaged p53 protein rather than trying to repair it
Shares PROTACs & molecular glues (targeted protein degradation), The undruggable drivers.
- ProductMezigdomide
Shares PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.
- IdeaDrag cancer's surface and secreted proteins to the cell's recycling bin
Shares PROTACs & molecular glues (targeted protein degradation), The undruggable drivers.